2017
Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load
Grothe M, Villeneuve S, Dyrba M, Bartrés-Faz D, Wirth M, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Liu E, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Ances B, Carroll M, Leon S, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, Leyla deToledo-Morrell P, Shah R, Duara R, Varon D, Roberts, CNA P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Coleman R, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Lu P, Bartzokis G, Silverman D, Graff-Radford, MBBCH N, Parfitt F, Johnson H, Farlow M, Hake A, Matthews B, Herring S, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Bwayo S, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha D, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Longmire C, Spicer K, Finger E, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Boles Ponto L, Shim H, Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj B. Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology 2017, 88: 569-576. PMID: 28062720, PMCID: PMC5304459, DOI: 10.1212/wnl.0000000000003585.Peer-Reviewed Original ResearchConceptsAPOE2 carriersGray matter volumeAmyloid loadAmyloid pathologyAged brainAPOE2 alleleDisease Neuroimaging InitiativeMatter volumeCross-sectional multimodalRegional amyloid loadTypical age-related increaseAlzheimer's disease biomarkersVoxel-wise analysisAge-related increaseAlzheimer's Disease Neuroimaging InitiativeApoE3 homozygotesInterest-based analysisFluorodeoxyglucose PETTau pathologyAmyloid depositionAPOE3 genotypeParietal metabolismAV45-PETHippocampal volumeBrain changes
2016
Accelerating rates of cognitive decline and imaging markers associated with &bgr;-amyloid pathology
Insel P, Mattsson N, Mackin R, Schöll M, Nosheny R, Tosun D, Donohue M, Aisen P, Jagust W, Weiner M, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Liu E, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Ances B, Carroll M, Leon S, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts, CNA P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Coleman R, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Lu P, Bartzokis G, Silverman D, Graff-Radford, MBBCH N, Parfitt F, Johnson H, Farlow M, Hake A, Matthews B, Herring S, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Bwayo S, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Longmire C, Spicer K, Finger E, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Boles Ponto L, Shim H, Elizabeth Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Ashok Raj B. Accelerating rates of cognitive decline and imaging markers associated with &bgr;-amyloid pathology. Neurology 2016, 86: 1887-1896. PMID: 27164667, PMCID: PMC4873684, DOI: 10.1212/wnl.0000000000002683.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmyloid beta-PeptidesAniline CompoundsAtrophyBiomarkersBrainCognitionCognitive DysfunctionDisease ProgressionEthylene GlycolsFemaleFluorodeoxyglucose F18HumansLongitudinal StudiesMagnetic Resonance ImagingMaleMental Status ScheduleNeuropsychological TestsPeptide FragmentsPositron-Emission TomographyRadiopharmaceuticalsRegression AnalysisConceptsMild cognitive impairmentFunctional declineNeuronal injuryCSF Aβ42Florbetapir PETAmyloid positivityRate of declineCognitive declineTemporal lobe atrophy ratesΒ-amyloid pathologyEarly Alzheimer's diseaseFluorodeoxyglucose PETAmyloid pathologyFDG-PETFuture trialsAtrophy ratesInclusion criteriaMixed-effects regressionΒ-amyloidCognitive impairmentAlzheimer's diseaseFirst signPatientsInjuryConsiderable proportion
1991
Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography
Tune L, Brandt J, Frost J, Harris G, Mayberg H, Steele C, Burns A, Sapp J, Folstein M, Wagner H, Pearlson G. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatrica Scandinavica. Supplementum 1991, 83: 61-65. PMID: 1897377, DOI: 10.1111/j.1600-0447.1991.tb03111.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlzheimer DiseaseAmphetaminesBlood GlucoseBrainCerebrovascular CirculationDeoxyglucoseDose-Response Relationship, DrugDrug Administration ScheduleFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedNeuropsychological TestsPhysostigminePilot ProjectsTomography, Emission-ComputedTomography, Emission-Computed, Single-PhotonConceptsCerebral glucose metabolismCerebral blood flowSingle photon emission tomographyPhoton emission tomographyPositron emission tomographyBlood flowEmission tomographyGlucose metabolismAlzheimer's diseaseRegional cerebral glucose metabolismSignificant clinical improvementCognitive functioningClinical improvementMost patientsIntravenous administrationPatientsDiseasePhysostigmineTomographyBrain activityPreliminary findingsMetabolismPronounced improvementPathophysiologyIllness